Pharmacy No. 84. Delivery of medicines to your home and office.

Delivery on Sundays and holidays does not work!

Medicines

my basket

Apteka84.kz is an online pharmacy that offers its customers medicines, medicinal and decorative cosmetics, dietary supplements, vitamins, baby food, intimate products for adults, medical equipment and thousands of other medical and cosmetic products at low prices. All data presented on the Apteka84.kz website is for informational purposes only and is not a substitute for professional medical care. Apteka84.kz strongly recommends that you carefully read the instructions for use contained in each package of medicines and other products. If you currently have any symptoms of the disease, you should seek help from a doctor. You should always tell your doctor or pharmacist about all the medicines you take. If you feel you need further help, please consult your local pharmacist or contact our GP online or by telephone.

Neurox, 125 mg, film-coated tablets, 30 pcs.

Ethylmethylhydroxypyridine succinate is an inhibitor of free radical processes, a membrane protector with antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic effects.

Ethylmethylhydroxypyridine succinate increases the body's resistance to various damaging factors (shock, hypoxia and ischemia, cerebrovascular accidents, intoxication with alcohol and antipsychotics (neuroleptics)).

The mechanism of action of ethylmethylhydroxypyridine succinate is due to its antioxidant, antihypoxic and membrane protective effects. It inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces membrane viscosity, and increases its fluidity. Ethylmethylhydroxypyridine succinate modulates the activity of membrane-bound enzymes (calcium independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, gamma-aminobutyric acid, acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional organization of biomembranes, neurotransmitter transport and improve synaptic transmission . Ethylmethylhydroxypyridine succinate increases dopamine levels in the brain. Causes an increase in compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of adenosine triphosphate and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, stabilization of cell membranes.

Improves metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, reduces platelet aggregation. Stabilizes the membrane structures of blood cells (erythrocytes and platelets) during hemolysis.

It has a lipid-lowering effect, reduces the content of total cholesterol and low-density lipoproteins.

The anti-stress effect is manifested in the normalization of post-stress behavior, somatovegetative disorders, restoration of sleep-wake cycles, impaired learning and memory processes, reduction of dystrophic and morphological changes in various structures of the brain.

Ethylmethylhydroxypyridine succinate has a pronounced antitoxic effect in withdrawal symptoms. Eliminates neurological and neurotoxic manifestations of acute alcohol intoxication, restores behavioral disorders, autonomic functions, and is also able to relieve cognitive impairment caused by long-term use of ethanol and its withdrawal.

Under the influence of ethylmethylhydroxypyridine succinate, the effect of tranquilizing, neuroleptic, antidepressant, hypnotics and anticonvulsants is enhanced, which makes it possible to reduce their doses and reduce side effects.

Ethylmethylhydroxypyridine succinate improves the functional state of ischemic myocardium. In conditions of coronary insufficiency, it increases collateral blood supply to the ischemic myocardium, helps maintain the integrity of cardiomyocytes and maintain their functional activity. Effectively restores myocardial contractility in reversible cardiac dysfunction.

NEUROXON tablet p/o 500 mgN20

Compound:

active ingredient: citicoline;

1 tablet contains citicoline monosodium salt (in terms of citicoline) 500 mg;

excipients: microcrystalline cellulose; croscarmellose sodium; polyethoxylated castor oil, hydrogenated with the mineral carrier magnesium aluminometasilicate; talc; silicon dioxide colloidal hydrophobic; magnesium stearate; coating mixture "Aquarius Prime BKN318029 White", which contains hydroxypropyl methylcellulose, hydroxypropylcellulose, medium chain triglycerides, titanium dioxide.

Dosage form. Film-coated tablets.

Pharmacotherapeutic group.

Psychostimulants, drugs used for attention deficit hyperactivity disorder (ADHD), and nootropics. ATC code N06B X06.

Clinical characteristics.

Indications.

— Acute phase of cerebrovascular accidents.

— Complications and consequences of cerebrovascular accidents.

— Traumatic brain injury and its consequences.

— Cognitive, sensitive, motor and neurological disorders caused by cerebral pathology of degenerative and vascular origin.

Contraindications .

- Hypersensitivity to the active substances or to any excipient.

— High tone of the parasympathetic nervous system.

Method of application and dose.

The recommended dose is from 500 to 2000 mg per day (1-4 tablets).

The dosage of the drug and the duration of treatment depend on the severity of brain damage and are determined by the doctor.

Elderly patients do not require dose adjustment.

Adverse reactions.

Adverse reactions occur very rarely (

From the nervous system: hallucinations, headache, dizziness.

From the cardiovascular system: arterial hypertension, arterial hypotension.

From the respiratory system: dyspnea.

From the digestive tract: nausea, vomiting, diarrhea.

From the skin and subcutaneous tissues: redness, urticaria, exanthema.

General disorders: trembling, swelling.

Overdose.

No cases of overdose have been reported.

Use during pregnancy or breastfeeding.

A drug is prescribed during pregnancy only when the expected benefit to the mother outweighs the potential risk to the fetus.

Data on the passage of citicoline into breast milk and its effect on the baby are unknown.

Children .

There is insufficient data on the use of the drug in children.

Features of application.

No.

The ability to influence the reaction rate when driving a vehicle or working with other mechanisms.

In individual cases, some adverse reactions from the central nervous system may affect the ability to drive vehicles or operate complex machinery.

Drug interactions and other types of interactions.

Citicoline enhances the effect of levodopa. Should not be administered concomitantly with medicinal products containing meclofenoxate.

Pharmacological properties

Pharmacodynamics.

Citicoline stimulates the biosynthesis of structural phospholipids in the membrane of neurons, which helps improve membrane functions, including the functioning of ion exchange pumps and neuroreceptors. Due to its stabilizing effect on the membrane, citicoline has anti-edematous properties and reduces cerebral edema. Citicoline inhibits the activity of certain phospholipases, prevents the release of free radicals, prevents damage to membrane systems and ensures the preservation of the protective antioxidant system.

Citicoline reduces the volume of damaged tissue, preventing cell death, acting on the mechanisms of apoptosis, and improves cholinergic transmission. Citicoline also has a preventive neuroprotective effect in focal cerebral strokes. Citicoline promotes rapid functional rehabilitation of patients with acute cerebrovascular accidents, reducing ischemic damage to brain tissue. which is confirmed by the results of X-ray studies.

In case of traumatic brain injury, citicoline shortens the duration of the recovery period and reduces the intensity of post-traumatic syndrome.

Citicoline helps to increase the level of brain activity, reduces the level of amnesia, and improves the condition of cognitive, sensory and motor disorders that are observed with cerebral ischemia.

Pharmacokinetics.

Citicoline is well absorbed when taken orally. After taking the drug, a significant increase in the level of cholines in the blood plasma is observed. When administered orally, the drug is almost completely absorbed. Bioavailability via oral and parenteral routes of administration is almost the same.

The drug is metabolized in the intestines and liver with the formation of choline and cytidine. After administration, citicoline is absorbed by brain tissue, while cholines act on phospholipids, cytidine - on cytidine nucleoids and nucleic acids. Citicoline quickly reaches brain tissue and is actively integrated into cell membranes, cytoplasm and mitochondria, activating the activity of phospholipids.

Only a small amount of the administered dose is excreted in urine and feces (less than 3%). Approximately 12% of the administered dose is excreted through the respiratory tract. Excretion of the drug in the urine and through the respiratory tract has two phases: the first phase is rapid excretion (with urine - during the first 36 hours, through the respiratory tract - during the first 15 hours), the second phase is slow elimination. The main part of the drug dose is involved in metabolic processes.

Pharmaceutical characteristics.

Basic physicochemical properties: film-coated tablets, white, oval, with a biconvex surface, with a score on one side of the tablet.

Best before date. 2 years.

Storage conditions.

Store in original packaging at a temperature not exceeding 25 ºС.

Keep out of the reach of children.

Package.

10 tablets in a blister, 2 or 3 blisters in a pack.

Vacation category. On prescription.

Neuroxon 500 mg/4 ml No. 10 solution d/in.

NEUROXON Trade name Neuroxone International nonproprietary name Citicoline (citicoline) Dosage form Solution for injection 500 mg/4 ml, 1000 mg/4 ml Composition 1 ampoule of the drug contains: active substance - citicoline sodium (in terms of citicoline) - 522.5 mg or 1045.0 mg (500.0 mg or 1000.0 mg) excipient – water for injection Description Transparent colorless liquid Pharmacotherapeutic group Psychoanaleptics. Psychostimulants and nootropics. Other psychostimulants and nootropics. Citicoline. ATX code N06B X06 Pharmacological properties Pharmacokinetics. Citicoline is well absorbed when administered intramuscularly and intravenously. After administration of the drug, a significant increase in the level of cholines in the blood plasma is observed. When administered orally, the drug is almost completely absorbed. Studies have shown that bioavailability through oral and parenteral routes of administration is almost the same. The drug is metabolized in the intestines and liver with the formation of choline and cytidine. After administration, citicoline is absorbed by brain tissue, while cholines act on phospholipids, cytidine - on cytidine nucleoids and nucleic acids. Citicoline quickly reaches brain tissue and is actively integrated into cell membranes, cytoplasm and mitochondria, activating the activity of phospholipids. Only a small amount of the administered dose is excreted in urine and feces (less than 3%). Approximately 12% of the administered dose is excreted through the respiratory tract. Excretion of the drug through the urine and through the respiratory tract has two phases: the first phase is rapid elimination (with urine - during the first 36 hours, through the respiratory tract - during the first 15 hours), the second phase is slow release. The main part of the drug dose is involved in metabolic processes. Pharmacodynamics. Citicoline stimulates the biosynthesis of structural phospholipids in the membrane of neurons, which helps improve membrane functions, including the functioning of ion exchange pumps and neuroreceptors. Due to its stabilizing effect on the membrane, citicoline has anti-edematous properties, therefore reducing brain edema. Citicoline inhibits the activity of some phospholipases, prevents the residual release of free radicals, prevents damage to membrane systems and ensures the preservation of the protective antioxidant system. Citicoline reduces the volume of damaged tissue, preventing cell death, acting on the mechanisms of apoptosis, and improves cholinergic transmission. Citicoline also has a preventive neuroprotective effect in focal cerebral strokes. Citicoline promotes rapid functional rehabilitation of patients with acute cerebrovascular accidents, reducing ischemic damage to brain tissue, which is confirmed by the results of X-ray studies. In case of traumatic brain injury, citicoline shortens the duration of the recovery period and reduces the intensity of post-traumatic syndrome. Citicoline helps to increase the level of brain activity, reduces the level of amnesia, and improves the condition of cognitive, sensory and motor disorders that are observed with cerebral ischemia. Indications for use: acute phase of cerebrovascular accidents and treatment of complications and consequences of cerebrovascular accidents. - traumatic brain injury and its consequences. - neurological disorders (cognitive, sensitive, motor) caused by cerebral pathology of degenerative and vascular origin. Method of administration and dosage For intravenous or intramuscular administration. The recommended dose for adults is from 500 mg to 2000 mg per day. The first 2 weeks, 500-1000 mg 2 times a day intravenously, then 500-1000 mg 2 times a day intramuscularly. The maximum daily dose is 2000 mg. In acute and emergency conditions, the maximum therapeutic effect is achieved when the drug is prescribed in the first 24 hours. If necessary, treatment is continued with Neuroxon, an oral solution. The recommended course of treatment, in which the maximum therapeutic effect is observed, is 12 weeks. The dosage of the drug and the duration of treatment depend on the severity of brain damage and are determined by the doctor individually. Intravenously is prescribed as a slow intravenous injection (over 3-5 minutes, depending on the dose administered) or intravenous drip (40-60 drops per minute). Elderly patients do not require dose adjustment. Side effects Adverse reactions occur very rarely (<1/10000), including isolated cases. - nausea, vomiting, diarrhea - arterial hypertension, arterial hypotension, tachycardia - severe headache, dizziness, feeling of heat, tremor - hallucinations, agitation - dyspnea - chills, swelling, allergic reactions, including: rash, purpura, urticaria, itching , angioedema, anaphylactic shock, increased body temperature, increased sweating, changes at the injection site, redness of the skin up to purple coloring. Contraindications: hypersensitivity to the components of the drug. - increased tone of the parasympathetic nervous system. Drug interactions Citicoline enhances the effect of levodopa. Should not be administered concomitantly with medicinal products containing meclofenoxate. Special instructions In case of persistent intracranial hemorrhage, the dose should not exceed 1000 mg per day and the intravenous rate of 30 drops per minute. The drug is used immediately after opening the ampoule. The ampoule with the drug is intended for single use only. Remains of the drug must be destroyed. Use during pregnancy and lactation. There is insufficient data regarding the use of Neuroxone in pregnant women. Data on the excretion of citicoline into breast milk and its effect on the fetus are not known. Therefore, during pregnancy or breastfeeding, the drug is prescribed only when the expected benefit to the mother outweighs the potential risk to the fetus. Use in pediatrics There is insufficient data regarding the use of Neuroxone in children. The drug is used in cases of emergency, when the expected benefit of use outweighs the potential risk. Peculiarities of the effect of the drug on the ability to drive a vehicle or operate potentially dangerous mechanisms. In some cases, some adverse reactions from the central nervous system may affect the ability to drive vehicles and work with complex mechanisms. Overdose Cases of overdose have not been described. In case of occurrence, symptoms of overdose are manifested by increased side effects of the drug. Treatment: symptomatic. Release form and packaging 4 ml of the drug (500 mg/4 ml) in 5 ml neutral glass ampoules with a ring or with a break point or 4 ml of the drug (1000 mg/4 ml) in 5 ml neutral glass ampoules with a ring red fracture (Panton 186C). 5 ampoules are placed in a blister pack or 5 ampoules are placed in a blister pack covered with film. 2 blister packs together with instructions for medical use in the state and Russian languages are placed in a pack. Storage conditions Store in original packaging at a temperature not exceeding 30 °C. Keep out of the reach of children! Shelf life: 2 years Do not use after expiration date Conditions for dispensing from pharmacies By prescription. , Ukraine, 79024, Lviv, st. Oprshkovskaya, 6/8.